GNE-617 showed robust antitumor activity in NAPRT-deficient xenograft mouse models, including prostate (PC3) cancer, fibrosarcoma (HT1080), and pancreatic (MiaPaCa-2) cancer, and resulted in more than 98% of the NAD reduction in tumors in vivo [190]. Here, NAPRT is linked to fibrosarcoma.